アラバマ州における子宮内膜がんの臨床試験
アラバマ州内の拠点で、子宮内膜がんに関する19件の研究が参加者を募集しています。
アラバマ州内の都市
公式研究テキスト（英語）
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Alabama at Birmingham Cancer Center, Birmingham
- University of South Alabama Mitchell Cancer Institute, Mobile
被験者募集中第2相
全年齢 · 全性別 · 2026/10/02更新 · NCT05564377A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
- GSK Investigational Site, Birmingham
被験者募集中第3相
18歳以上 · 女性 · 2026/10/02更新 · NCT07286331Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- University of Alabama at Birmingham Cancer Center, Birmingham
被験者募集中第3相
18歳以上 · 女性 · 2026/10/02更新 · NCT07198074A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06760819177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- Dothan Hematology & Oncology, Dothan
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07189871Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- University of Alabama at Birmingham Cancer Center, Birmingham
被験者募集中第2相
18歳以上 · 女性 · 2026/09/28更新 · NCT05112601Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- University of Alabama_6th Ave, Birmingham
被験者募集中第1/2相
18歳以上 · 女性 · 2026/09/25更新 · NCT03564340A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- University of South Alabama, Mitchell Cancer Institute ( Site 6033), Mobile
被験者募集中第3相
18歳以上 · 女性 · 2026/09/17更新 · NCT06952504ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Alabama at Birmingham, Birmingham
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/14更新 · NCT05059444Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Alabama Birmingham, Birmingham
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- USAH Mitchell Cancer Inst, Mobile
被験者募集中第3相
18歳以上 · 女性 · 2026/09/09更新 · NCT07166094Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Alabama, Birmingham
被験者募集中第1/2相
12 Months – 30 Years · 全性別 · 2026/08/25更新 · NCT04851119A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- University of Alabama at Birmingham, Birmingham
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/30更新 · NCT04657068The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
- University of Alabama at Birmingham, Birmingham
被験者募集中観察研究健康なボランティア歓迎
18歳〜99歳 · 女性 · 2026/07/29更新 · NCT03538665A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University of Alabama at Birmingham, Birmingham
- University of Alabama at Birmingham, IDS Pharmacy, Birmingham
- University of Alabama at Birmingham, Birmingham
- 他1件
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/22更新 · NCT05208762Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 004, Birmingham
被験者募集中第2相
18歳以上 · 女性 · 2026/07/16更新 · NCT06906341Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
- O'Neal Comprehensive Cancer Center at UAB, Birmingham
被験者募集中第1/2相
18歳以上 · 女性 · 2026/04/15更新 · NCT05559879SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。